Avid Bioservices Inc (CDMO)

[freethemice]

Here is a paper which has similar results but in NSCLC. Again a retrospective look at patient samples from surgery.
Here I take "tumor islets" as being the tumor tissue, and tumor stoma as the surrounding tissues.
The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time
BMC Cancer 2010
FREE: http://www.biomedcentral.com/content/pdf/1471-2407-10-112.pdf
------------------------------------------------------------------------------------------------------------
Abstract
Background: Tumor-associated macrophages (TAMs) play an important role in growth, progression and metastasis
of tumors. In non-small cell lung cancer (NSCLC), TAMs’ anti-tumor or pro-tumor role is not determined.
Macrophages are polarized into M1 (with anti-tumor function) and M2 (with pro-tumor function) forms. This study
was conducted to determine whether the M1 and M2 macrophage densities in NSCLC are associated with
patient’s survival time.
Methods: Fifty patients with an average of 1-year survival (short survival group) and 50 patients with an average of
5-year survival (long survival group) were included in this retrospective study. Paraffin-embedded NSCLC specimens
and their clinicopathological data including up to 8-year follow-up information were used. Immunohistochemical
double-staining of CD68/HLA-DR (markers for M1 macrophages) and CD68/CD163 (markers for M2 macrophages)
was performed and evaluated in a blinded fashion. The M1 and M2 macrophage densities in the tumor islets,
stroma, or islets and stroma were determined using computer-aided microscopy. Correlation of the macrophage
densities and patient’s survival time was analyzed using the Statistical Package for the Social Sciences.
Results: Approximately 70% of TAMs were M2 macrophages and the remaining 30% were M1 macrophages in
NSCLC. The M2 macrophage densities (approximately 78 to 113 per mm2) in the tumor islets, stroma, or islets and
stroma were not significantly different between the long survival and short survival groups. The M1 macrophage
densities in the tumor islets (approximately 70/mm2) and stroma (approximately 34/mm2) of the long survival
group were significantly higher than the M1 macrophage densities in the tumor islets (approximately 7/mm2) and
stroma (13/mm2) of the short survival group (P < 0.001 and P < 0.05, respectively). The M2 macrophage densities
were not associated with patient’s survival time. The M1 macrophage densities in the tumor islets, stroma, or islets
and stroma were positively associated with patient’s survival time in a univariate analysis (P < 0.01 or 0.001). In a
multivariate Cox proportional hazards analysis, the M1 macrophage density in the tumor islets was an independent
predictor of patient’s survival time.
Conclusions: The M1 macrophage density in the tumor islets is an independent predictor of survival time in
NSCLC patients.
------------------------------------------------------------------------------------------------------------
Here are the survival curves for the different categories. Survival was much better if there was a higher than median number of
M1 macrophages in the tumors.